Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

bluebird bio Inc. is resolute in its determination to negotiate a five-year €315,000 ($356,000) annual payment model for its new gene therapy Zynteglo in Europe. The company laid out the price of the one-time gene therapy on 14 June in a strategy meant to manage some of the sticker shock associated with a seven-figure drug price by balancing the cost with a risk-based model annuitized over five years.

The price of Zynteglo is set at €1.575m ($1.78m) over the five years, if the treatment is successful, based on a reduction in the number of blood transfusions. Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) was granted European marketing authorization on 3 June after a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) in March